Sujata Patil, PhD

Associate Attending Biostatistician

Sujata Patil, PhD

Office Phone



University of Michigan

Current Research Interests

Dr. Patil’s biostatistical research interests are in longitudinal data analysis, survival analysis, clinical trial design, analysis of incomplete data, measurement error models, and Bayesian methods. Dr. Patil uses these methods routinely in her clinical collaborations with oncologists and surgeons in the Genitourinary, Breast, and Colorectal Surgery Services, where she serves as the primary faculty statistician. Dr. Patil’s current methodologic work is in two areas: developing approaches to compare cumulative risk distributions of two events; and how to design studies where there are competing events. In completed work, she has examined stage migration in metastatic renal cell carcinoma over the last four decades in internal and external datasets. Dr. Patil serves as a faculty lecturer for the Department of Surgery Clinical Research Methods Lecture Series and for the K30 Clinical Trial Symposium. With her colleague Dr. Satagopan, she is coordinator of a biostatistics course targeted to biomedical scientists at the Sloan Kettering Institute. She also serves on Research Council, MSK’s scientific review committee for all human subjects’ studies.


Selected peer-reviewed publications:

  1. Patil S, Ishill N, Deluca J, Motzer RJ. Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation. Cancer. 2010 Jan 15;116(2):347-54. PubMed [PMID:19921736].
  2. Patil S, Manola J, Elson P, Negrier S, Escudier B, Eisen T, Atkins M, Bukowski R, Motzer RJ. Improvement in Overall Survival in Patients with Advanced Renal Cell Carcinoma: Prognostic Factor Trend Analysis from an International Dataset of Clinical Trials. J Urol. 2012 Oct 17. doi:pii: S0022-5347(12)04483-7. 10.1016/j.juro.20108.026. [Epub ahead of print]
  3. Patil S, Figlin RA, Hutson TE, Michaelson MD, Negrier S, Kim ST, Huang X, Motzer RJ.Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib versus interferon-alfa, Br J Cancer. 2012 May 8;106(10):1587-90. doi: 10.1038/bjc.2012.149.
  4. Blinder V, Eberle C, Patil S, Gany FM, Bradley CJ. Women With Breast Cancer Who Work For Accommodating Employers More Likely To Retain Jobs After Treatment. Health Aff (Millwood). 2017 Feb 1;36(2):274-281. doi: 10.1377/hlthaff.2016.1196. PubMed [PMID:28167716].
  5. Van Zee KJ, Subhedar P, Olcese C, Patil S, Morrow M. Relationship Between Margin Width and Recurrence of Ductal Carcinoma In Situ: Analysis of 2996 Women Treated With Breast-conserving Surgery for 30 Years. Ann Surg. 2015 Oct;262(4):623-31. doi: 10.1097/SLA.0000000000001454. PubMed [PMID:26366541].

Visit PubMed for a full listing of Sujata Patil’s journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Sujata Patil discloses the following relationships and financial interests:

  • Second Science, Inc.
    Provision of Services

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at

View all disclosures